Rentschler will become the first CDMO to have access to Leukocare's SPS formulation technologies
Leukocare provides formulation platform for the protection of proteins like biopharmaceuticals and Rentschler is contract development and manufacturing organisation (CDMO) for bioprocess development and manufacturing of biopharmaceuticals, as well as for regulatory support.
Rentschler will acquire a 10% stake in Leukocare and Dr Frank Mathias, CEO of Rentschler, will join Leukocare’s Board of Directors. Leukocare’s ongoing and future business activities with pharma and biotech beyond the CDMO business will not be affected by this alliance.
“Our alliance brings to the forefront the importance of drug formulation as a key success factor in the development process.” — Dr Frank Mathias, CEO of Rentschler
Leukocare provides formulation development services based on its Stabilizing and Protecting Solutions (SPS), designed to improve the stability of therapeutic proteins; for example, liquid dose formulations to improve biopharmaceuticals at higher temperatures and provide them with a longer shelf-life.
SPS technologies improve stability and quality of biologics like antibodies, vaccines, etc. in dry and liquid formulation. SPS also protects proteins in biologically functionalised combination devices.
“This alliance will enable us to fully exploit the possibilities and advantages of the SPS formulation technologies,” said Michael Scholl, CEO of Leukocare.
Left, Frank Mathias. Right, Michael Scholl